Aminoglutethimide

This page contains recent news articles, when available, and an overview of Aminoglutethimide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Aminoglutethimide (when available)

Pharmacology and use:
Aminoglutethimide inhibits the enzymatic conversion of cholesterol to D5-pregnenolone, resulting in a decrease in the production of adrenal glucocorticoids, mineralocorticoids, estrogens, and androgens. For the suppression of adrenal function in selected patients with Cushing s syndrome, Malignant neoplasm of female breast, Carcinoma in situ of breast

Mechanism Of Action:
Aminoglutethimide reduces the production of D5-pregnenolone and blocks several other steps in steroid synthesis, including the C-11, C-18, and C-21 hydroxylations and the hydroxylations required for the aromatization of androgens to estrogens, mediated through the binding of Aminoglutethimide to cytochrome P-450 complexes. A decrease in adrenal secretion of cortisol is followed by an increased secretion of pituitary adrenocorticotropic hormone (ACTH), which will overcome the blockade of adrenocortical steroid synthesis by aminoglutethimide. The compensatory increase in ACTH secretion can be suppressed by the simultaneous administration of hydrocortisone. Since aminoglutethimide increases the rate of metabolism of dexamethasone but not that of hydrocortisone, the latter is preferred as the adrenal glucocorticoid replacement. Although aminoglutethimide inhibits the synthesis of thyroxine by the thyroid gland, the compensatory increase in thyroid-stimulating hormone (TSH) is frequently of sufficient magnitude to overcome the inhibition of thyroid synthesis due to aminoglutethimide. In spite of an increase in TSH, aminoglutethimide has not been associated with increased prolactin secretion.

News Articles on Aminoglutethimide

Melatonin: A Hormone That Protects Against Breast Cancer and Aging  -  Apr 10, 2008
...animals stimulated tumor growth, an effect that was suppressed by administration of melatonin or the aromatase inhibitor aminoglutethimide. Natural News.com,

New Data Confirm Benefit Of Extended Adjuvant Treatment With ...  -  19 Dec 2007
...adjuvant treatment with either 5 years of tamoxifen alone, or 5 years of adjuvant tamoxifen plus aminoglutethimide for the first 2 years of treatment. Medical News Today (press release),

Extended Aromatase Inhibitor Use Post-Tamoxifen Reduces Breast ...  -  Dec 12, 2007
It is also possible, they said, that prior exposure to the aromatase inhibitor aminoglutethimide in trial 6 may have, to some extent, reduced the efficacy MedPage Today,

Medroxyprogesterone Acetate Information - Drug Interactions, Uses ...  -  Sep 30, 2007
Aminoglutethimide (Cytadren) interacts with medroxyprogesterone. Every drug is capable of producing side effects. Many medroxyprogesterone users experience PR-GB.com (press release),

Switch from Tamoxifen to Aromatase Inhibitor May Improve Breast ...  -  Apr 11, 2007
Cancerpage.com,..."In the former trial with low dose aminoglutethimide we selected to switch after 3 years of tamoxifen, because this period of treatment with this

Switching from Tamoxifen to Aromatase Inhibitor Improves Survival ...  -  Apr 11, 2007
Cancer Consultants (press release),One group of women then switched to treatment with an aromatase agent (anastrozole or aminoglutethimide) or continued treatment with tamoxifen for an

Aromatase Inhibitors Prolong Survival Over Tamoxifen  Sep 21, 2006
First- and second-generation drugs -- Cytadren (aminoglutethimide), formestane, and fadrozole -- had no significant benefit compared to other agents, the ... -MedPage Today

Breast Cancer Patients Could Live Longer  Sep 20, 2006
Tests with first-generation (aminoglutethimide) or second-generation (formestane and fadrozole) agents indicated no significant survival benefits. ... -Haber Sağlık

Brand Names/Synonyms:
Aminoglutethimide is also known by the following brand names and/or synonymsAminoglutethimide; Cytadren; Dl-Aminoglutethimide; Doriden; Elipten; Glutethimide; Orimeten; P-Aminoglutethimide

Drug Category:
Aminoglutethimide is categorized under the following by the FDA: Antineoplastic Agents; Adrenergic Agents; ATC:L02BG01

Dosage Forms:
Tablet

Absorption:
Rapidly and completely absorbed grom GI tract

Interactions:
-->Interactions for Aminoglutethimide:

Cytadren accelerates the metabolism of dexamethasone; therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed.

Aminoglutethimide diminishes the effect of coumarin and warfarin.

Chemical IUPAC Name:
3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.